BioSig Technologies (BSGM) AI Stock Analysis

• Market Cap: $144.12M
• Dividend Yield: N/A
• Average Volume (3M): 634.60K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.73
• Revenue Growth: 122.22%
• EPS Growth: 79.08%
• Country: US
• Employees: 5
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Devices
• EPS (TTM): -0.14
• Shares Outstanding: 27,294,603
• 10 Day Avg. Volume: 886,007
• 30 Day Avg. Volume: 634,600
• PEG Ratio: -0.03
• Price to Book (P/B): -33.96
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.92
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $2.50
• Price Target Upside: -52.65% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 34 Underperform
• Price Target: ―

BioSig Technologies faces significant financial difficulties, with persistent losses, high leverage, and negative cash flow trends. While technical analysis indicates some short-term momentum, potential overbought conditions warrant caution. The negative P/E ratio further underscores valuation challenges and risks associated with the stock.

Positive Factors

Analyst Ratings

Analyst maintains a BUY rating and raises the 12-month price target to $2.75, suggesting significant upside from the current share price.

Market Potential

Regaining NASDAQ listing and the billion dollars market potential for PURE EP presents high rewards for the risks.

Product Development

The PURE EP system, a non-invasive class II device, is designed to provide essential diagnostic signals during cardiac catheter ablations, improving procedure precision.

Negative Factors

Business Operations

The company announced a major reorganization in which it terminated a significant number of its employees and substantially reduced business operations due to lack of capital.

Financial Health

The company has ~$0 in cash and ~$0 million in debt and needs to raise new capital soon if it wants to resume business.

Guidance

The company did not provide forward guidance.

BioSig Technologies Business Overview & Revenue Model

Company Description

BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.

How the Company Makes Money

BioSig Technologies generates revenue primarily through the sale and lease of its PURE EP System to hospitals and medical institutions. The company also earns money by providing ongoing support services, including maintenance and upgrades, to ensure optimal performance of its systems. Additionally, BioSig may enter into strategic partnerships and collaborations with other healthcare entities and technology providers to expand its market reach and enhance its technological offerings. Key revenue streams include direct sales, leasing agreements, and service contracts associated with the PURE EP System.

BioSig Technologies Financial Statement Overview

Summary

BioSig Technologies faces significant financial challenges with a negative income statement, balance sheet, and cash flow. There are consistent losses, negative equity, and cash constraints, indicating financial instability and a need for strategic restructuring.

Income Statement

BioSig Technologies shows a struggling income statement with declining revenues and consistently negative net income over the years. The TTM (Trailing-Twelve-Months) data reveals a worsening gross profit margin and net profit margin, indicating financial challenges. Revenue growth is erratic, and profitability metrics such as EBIT and EBITDA margins remain negative, reflecting operational inefficiencies.

Balance Sheet

The balance sheet of BioSig Technologies presents a concerning picture with negative stockholders' equity, indicating financial distress. The debt-to-equity ratio is uncalculated due to negative equity, posing a risk of insolvency. The equity ratio is also negative, and return on equity is not meaningful due to sustained losses, highlighting the company's weak financial stability.

Cash Flow

The cash flow statement reveals a negative free cash flow growth, although there is a slight improvement in operating cash flow relative to net income. However, free cash flow remains significantly negative, indicating ongoing cash burn. The reliance on financing activities for liquidity demonstrates a lack of sustainable cash generation from operations.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
39.00K	18.00K	286.00K	441.00K	0.00	0.00
	Gross Profit
-181.00K	18.00K	229.00K	242.00K	-550.00K	-54.35K
	EBIT
-17.59M	-28.51M	-27.27M	-33.41M	-59.18M	-34.60M
	EBITDA
-16.18M	-28.15M	-26.97M	-33.21M	-58.63M	-34.42M
	Net Income Common Stockholders
-15.28M	-29.04M	-27.27M	-31.36M	-52.17M	-33.92M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.51M	190.00K	458.00K	11.66M	28.27M	12.11M
	Total Assets
5.20M	1.80M	4.11M	15.52M	30.39M	14.22M
	Total Debt
689.00K	452.00K	765.00K	656.00K	314.00K	723.42K
	Net Debt
-723.00K	262.00K	408.00K	-11.00M	-27.95M	-11.39M
	Total Liabilities
3.18M	4.68M	3.71M	2.95M	5.11M	2.34M
	Stockholders Equity
2.08M	-2.91M	418.00K	12.35M	24.48M	11.36M
Cash Flow		Free Cash Flow
-7.23M	-17.50M	-21.87M	-26.94M	-26.69M	-15.77M
	Operating Cash Flow
-7.23M	-17.31M	-21.70M	-26.40M	-26.60M	-15.48M
	Investing Cash Flow
-4.00K	-186.00K	-168.00K	-542.00K	-87.00K	-285.93K
	Financing Cash Flow
7.46M	17.33M	10.57M	10.33M	42.85M	23.43M

BioSig Technologies Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.28
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BSGM, the sentiment is Positive. The current price of 5.28 is above the 20-day moving average (MA) of 2.25, above the 50-day MA of 1.26, and above the 200-day MA of 1.03, indicating a bullish trend. The MACD of 0.84 indicates Negative momentum. The RSI at 94.38 is Negative, neither overbought nor oversold. The STOCH value of 88.32 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BSGM.

BioSig Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	53 Neutral	$5.14B	3.03	-43.89%	2.83%	16.75%	-0.06%
VVOS	47 Neutral	$13.43M	―	-450.47%	―	9.47%	81.37%
PAVM	43 Neutral	$11.19M	0.91	-499.57%	―	-33.92%	―
CODX	42 Neutral	$7.81M	―	-56.80%	―	-91.22%	11.84%
ADGM	41 Neutral	$18.30M	―	-329.16%	―	2115.38%	-4.40%
BSGM	34 Underperform	$144.12M	―	5400.35%	―	122.22%	79.08%
AXDXQ	24 Underperform	$337.82K	―		―	-2.99%	59.87%

BioSig Technologies Corporate Events

BioSig Technologies Shareholders Support Strategic Proposals

BioSig Technologies held its Annual Meeting where four key proposals were submitted to stockholders for voting. The proposals included electing five directors to the board, approving a reverse stock split, increasing shares under the Incentive Plan, and ratifying Marcum LLP as the independent accounting firm. The votes resulted in the election of directors, approval of the reverse stock split and Incentive Plan Amendment, and ratification of the accounting firm, reflecting shareholder support for the company’s strategic decisions.